clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Parotitis D010309 4 associated lipids
Psittacosis D009956 4 associated lipids
Confusion D003221 4 associated lipids
Prurigo D011536 4 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Cysts D003560 4 associated lipids
Duodenitis D004382 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Foot Diseases D005534 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ergotism D004881 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Dyspepsia D004415 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Keshavarz AA et al. Omeprazole-based triple therapy with low-versus high-dose of clarithromycin plus amoxicillin for H pylori eradication in Iranian population. 2007 World J. Gastroenterol. pmid:17352026
Losurdo G et al. Role of concomitant therapy for eradication: A technical note. 2016 World J. Gastroenterol. pmid:27784977
Si JM et al. Quality of gastric ulcer healing evaluated by endoscopic ultrasonography. 2005 World J. Gastroenterol. pmid:15948255
Hagiwara T et al. Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection. 2007 World J. Gastroenterol. pmid:17657838
Huang JQ et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. 2005 World J. Gastroenterol. pmid:15884111
Robles-Jara C et al. Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? 2008 World J. Gastroenterol. pmid:18473407
Koussoulas V et al. Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease. 2007 World J. Gastroenterol. pmid:17729416
Gumurdulu Y et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. 2004 World J. Gastroenterol. pmid:14991935
Guo CY et al. Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. 2004 World J. Gastroenterol. pmid:14991953
Mirbagheri SA et al. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial. 2006 World J. Gastroenterol. pmid:16937475
Attaran B et al. Effect of biofilm formation by clinical isolates of on the efflux-mediated resistance to commonly used antibiotics. 2017 World J. Gastroenterol. pmid:28275296
Ching SS et al. Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. 2008 World J. Gastroenterol. pmid:18609709
Trifan A et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. 2013 World J. Gastroenterol. pmid:24259981
Iannone A et al. New fecal test for non-invasive detection: A diagnostic accuracy study. 2018 World J. Gastroenterol. pmid:30038469
Lee HJ et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. 2015 World J. Gastroenterol. pmid:25574111
Brennan DE et al. Can bacterial virulence factors predict antibiotic resistant infection? 2018 World J. Gastroenterol. pmid:29531461
Buzás GM and Józan J First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. 2006 World J. Gastroenterol. pmid:16981260
Babic Z et al. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. 2005 World J. Gastroenterol. pmid:15884110
Wang B et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. 2014 World J. Gastroenterol. pmid:25356059
Ji F et al. Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. 2006 World J. Gastroenterol. pmid:16586550
Zhou Q et al. Drug utilization of clarithromycin for gastrointestinal disease treatment. 2008 World J. Gastroenterol. pmid:18932287
Sereni G et al. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. 2012 World J. Gastroenterol. pmid:22969227
Isomoto H et al. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. 2005 World J. Gastroenterol. pmid:15786539
Wang HH et al. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. 2005 World J. Gastroenterol. pmid:15786549
Aydemir S et al. Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. 2005 World J. Gastroenterol. pmid:15682477
Wang CH et al. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. 2015 World J. Gastroenterol. pmid:26494972
Sun WH et al. Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. 2005 World J. Gastroenterol. pmid:15832421
Bustamante-Rengifo JA et al. Effect of treatment failure on the CagA EPIYA motif in strains from Colombian subjects. 2017 World J. Gastroenterol. pmid:28373764
Hwang JJ et al. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. 2015 World J. Gastroenterol. pmid:26401089
Zhao LJ et al. Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype. 2014 World J. Gastroenterol. pmid:24782630
Nishida T et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. 2014 World J. Gastroenterol. pmid:24764674
Gao XZ et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. 2010 World J. Gastroenterol. pmid:20818821
Garza-González E et al. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. 2014 World J. Gastroenterol. pmid:24587620
Grande M et al. Helicobacter pylori and gastroesophageal reflux disease. 2008 World J Surg Oncol pmid:18601740
Cavanna L et al. High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. 2008 World J Surg Oncol pmid:18353178
Whittemore KR and Cohen M Imaging and review of a large pre-auricular pilomatrixoma in a child. 2012 World J Radiol pmid:22761984
Yanai A et al. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. 2012 World J Gastrointest Pharmacol Ther pmid:22408744
Francesco VD et al. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. 2011 World J Gastrointest Pathophysiol pmid:21860834
Bago P et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. 2007 Wien. Klin. Wochenschr. pmid:17634896
Bago J et al. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial. 2002 Wien. Klin. Wochenschr. pmid:12422579
Bago J et al. Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. 2004 Wien. Klin. Wochenschr. pmid:15379146
Vcev A et al. Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). 2001 Wien. Klin. Wochenschr. pmid:11802510
Li Y et al. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. 2010 Wien. Klin. Wochenschr. pmid:20628905
Nizič T et al. Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin. 2012 Wien. Klin. Wochenschr. pmid:22760494
Kurz H and Göpfrich H [Epidemiology and morbidity of mycoplasma as causative agent for community-acquired pneumonia in hospitalized children in a Community Hospital in Vienna]. 2011 Wien Med Wochenschr pmid:20963506
Kardas P and Muras M [A blinded comparison of palatability of 13 common pediatric antibiotic suspensions]. 2005 Wiad. Lek. pmid:15991547
Gościmski A et al. [Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor]. 2002 Wiad. Lek. pmid:12043311
Dhawan VK et al. Vancomycin-resistant enterococcal colonization in nonhospitalized HIV-infected patients. 1998 West. J. Med. pmid:9830355
Kanatani MS and Guglielmo BJ The new macrolides. Azithromycin and clarithromycin. 1994 West. J. Med. pmid:8128699
Feng X et al. [Interaction between biofilm formed by Pseudomonas aeruginosa and antibacterial agents]. 2000 Wei Sheng Wu Xue Bao pmid:12548947